- Home
- DRCT vs VTVT Comparison
DRCT vs VTVT Comparison
Compare DRCT & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRCT
- VTVT
- Stock Information
- Founded
- DRCT 2018
- VTVT 2015
- Country
- DRCT United States
- VTVT United States
- Employees
- DRCT N/A
- VTVT N/A
- Industry
- DRCT Computer Software: Programming Data Processing
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- DRCT Technology
- VTVT Health Care
- Exchange
- DRCT Nasdaq
- VTVT Nasdaq
- Market Cap
- DRCT 8.8M
- VTVT 54.4M
- IPO Year
- DRCT 2022
- VTVT 2015
- Fundamental
- Price
- DRCT $0.34
- VTVT $20.75
- Analyst Decision
- DRCT Strong Buy
- VTVT Strong Buy
- Analyst Count
- DRCT 1
- VTVT 2
- Target Price
- DRCT $6.00
- VTVT $35.50
- AVG Volume (30 Days)
- DRCT 6.5M
- VTVT 4.6K
- Earning Date
- DRCT 11-11-2025
- VTVT 11-11-2025
- Dividend Yield
- DRCT N/A
- VTVT N/A
- EPS Growth
- DRCT N/A
- VTVT N/A
- EPS
- DRCT N/A
- VTVT N/A
- Revenue
- DRCT $36,459,000.00
- VTVT $17,000.00
- Revenue This Year
- DRCT $16.81
- VTVT N/A
- Revenue Next Year
- DRCT $35.28
- VTVT N/A
- P/E Ratio
- DRCT N/A
- VTVT N/A
- Revenue Growth
- DRCT N/A
- VTVT N/A
- 52 Week Low
- DRCT $0.28
- VTVT $12.62
- 52 Week High
- DRCT $6.59
- VTVT $26.99
- Technical
- Relative Strength Index (RSI)
- DRCT 46.82
- VTVT 48.04
- Support Level
- DRCT $0.31
- VTVT $19.80
- Resistance Level
- DRCT $0.39
- VTVT $23.05
- Average True Range (ATR)
- DRCT 0.05
- VTVT 1.10
- MACD
- DRCT 0.01
- VTVT -0.51
- Stochastic Oscillator
- DRCT 26.41
- VTVT 20.39
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin, being investigated for the treatment of type 1 diabetes (T1D). Its product pipeline includes TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.